Myelin oligodendrocyte glycoprotein-antibody (MOG-ab)-associated disease (MOGAD) or MOG-immunoglobulin G (MOG-IgG)-associated encephalomyelitis (MOG-EM) has been recognized as a distinct neuroimmunological disorder with specific clinical features and management (1). This evidence concerns the gene MOG and encephalomyelitis.